Boehringer Ingelheim Limited

Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
Telephone: +44 (0)1344 424 600
Fax: +44 (0)1344 741 298
WWW: http://www.boehringer-ingelheim.co.uk
Medical Information Direct Line: +44 (0)1344 741 286
Medical Information e-mail: medinfo@bra.boehringer-ingelheim.com
Summary of Product Characteristics last updated on the eMC: 30/03/2009
SPC Alupent Syrup

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 30/03/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 4.4

To add statement regarding ‘myocardial ischaemia’

 

Section 4.8

To add side effect regarding ‘myocardial ischaemia’

 

Section 10

Date revised to February 2009.

Updated on 27/08/2003 and displayed until 30/03/2009
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 06/12/2002 and displayed until 27/08/2003
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
Updated on 18/07/2002 and displayed until 06/12/2002
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   orciprenaline sulphate


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk